Marshall Wace North America’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Marshall Wace North America’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$443K	Buy	+17,424	New	+$512K	﹤0.01%	1152
2020 Q4	–	Sell	-259,168	Closed	-$14.3M	–	1684
2020 Q3	$14.3M	Sell	259,168 -276,108	-52%	-$17.5M	0.09%	230
2020 Q2	$33.8M	Buy	535,276 +450,108	+528%	+$30.9M	0.22%	114
2020 Q1	$4.35M	Buy	85,168 +82,392	+2,968%	+$5.52M	0.03%	345
2019 Q4	$221K	Sell	2,776 -5,014	-64%	-$297K	﹤0.01%	953
2019 Q3	$378K	Buy	+7,790	New	+$406K	﹤0.01%	851
2018 Q3	–	Sell	-132,283	Closed	-$5.98M	–	1495
2018 Q2	$5.98M	Buy	+132,283	New	+$6.02M	0.03%	473
2017 Q4	–	Sell	-22,178	Closed	-$688K	–	1683
2017 Q3	$688K	Buy	+22,178	New	+$624K	﹤0.01%	1019
2017 Q2	–	Sell	-18,751	Closed	-$694K	–	1503
2017 Q1	$694K	Buy	+18,751	New	+$472K	0.01%	758

Other funds holding GBT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Marshall Wace North America's GBT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q3 2021: 17,424 shares worth $443K. The stake represents ﹤0.01% of the portfolio and ranks #1152 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in GBT as recently as Q3 2020.

Marshall Wace North America first reported a position in GBT in Q1 2017 and has held it in 9 quarters since. The position peaked at $33.8M in Q2 2020. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

Marshall Wace North America held 17,424 shares of Global Blood Therapeutics, Inc. worth $443K as of Q3 2021.
Global Blood Therapeutics, Inc. was a new Marshall Wace North America position in Q3 2021.
Global Blood Therapeutics, Inc. made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1152 holding.
Marshall Wace North America first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and has held it in 9 quarters since.
Marshall Wace North America's Global Blood Therapeutics, Inc. position peaked at $33.8M in Q2 2020.
187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.